Citations

Clear

2960 citation(s) found for "Kim, P".

S1071 GLP-1 Agonist Use is Associated With Lower Complications and Mortality in Patients With Ulcerative Colitis and Obesity: A National Database Analysis
Narvaez, Sharon, Kim, Do Han , Ko, Donghyun , Chawla, Saurabh, Davisson, Laura , Kinnucan, Jami , Nieto, Luis M., Kim, Do Han , Ko, Donghyun , Vega, Kenneth J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S759-S759

10.14309/01.ajg.0001033652.14646.a5 Get It

S1193 Improvement in Disease-Related Biomarkers With an Adjuvant Treatment for 180 Days: Results From an Interventional Trial for Patients With Ulcerative Colitis
Turgeon, D. Kim , McClintock, Shannon D., Moraga, Gillian, Harber, Isabelle , McNeely, Molly M. , Varani, James, Aslam, Muhammad N. , Jencks, Kara J. , Stidham, Ryan W , Allen, Ron

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S848-S848

10.14309/01.ajg.0001034140.69061.d8 Get It

S894 Outcomes and Complications in Patients With Stimulant Abuse, Admitted for NVUGIB: A 2016-2020 United States National Analysis
Smadi, Khaled Al , Palacios, Pedro , Kim, Do Han , Flocco, Gianina, Saffouri, George, Paredes, Harold, Salazar, Miguel J. , Kim, Do Han , Dong, Ko

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S622-S623

10.14309/01.ajg.0001032944.73150.92 Get It

S750 Risk of Constipation and Slow Transit Constipation in Pre- and Peri-Menopause, Non-Obese Women on Progestogen-Only Contraceptives Versus Combined OCP: A Multi-Center Analysis
Ko, Donghyun , Narvaez, Sharon, Palacios-Argueta, Pedro, Lukens, Frank , Kim, Do Han , Salazar, Miguel J. , Nieto, Luis, Palacios-Argueta, Pedro, Kröner, Paul T.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S516-S516

10.14309/01.ajg.0001032368.98589.c3 Get It

S647 Balloon Cryotherapy is Highly Effective in Patients With Poor Response to Radiofrequency Ablation Therapy for Dysplastic Barrett’s Esophagus: Preliminary Results from the NO FEAR-BE Study
Shaheen, Nicholas J. , Iyer, Prasad G. , Khara, Harshit S. , Elias, Puja S., Chak, Amitabh , Shafa, Shervin , Peter, Shajan, Smith, Michael S. , Moist, Susan E., Walker, Kacie B, Kim, Julia , Jones, Carson, Canto, Marcia Irene , Cotton, Cary C. , Abrams, Julian A , Thosani, Nirav C , Cortright, Lindsay M. , Walker, Kacie B., Jones, Carson, Trindade, Arvind J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S448-S448

10.14309/01.ajg.0001031956.24377.ea Get It

S567 GLP-1 RAs Use is Associated with Lower 7-Days Repeat Esophagogastroduodenoscopy after Index Endoscopy in Patients with Achalasia: A Multi-Center Analysis
Ko, Donghyun , Narvaez, Sharon, Nieto, Luis, Palacios-Argueta, Pedro, Lukens, Frank , Kim, Do Han , Nieto, Luis, Kröner, Paul T.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S393-S393

10.14309/01.ajg.0001031636.70614.ca Get It

S560 GLP-1 Agonists Use Is Associated With Lower Use of PPI and Do Not Worsen Outcomes in Patients With GERD: A National Database Analysis
Narvaez, Sharon, Palacios-Argueta, Pedro, Ko, Donghyun , Chawla, Saurabh, Davisson, Laura , Nieto, Luis M., Palacios-Argueta, Pedro, Kim, Do Han , Vega, Kenneth J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S388-S389

10.14309/01.ajg.0001031608.30677.6c Get It

Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Long, Jessica B., Sprenkle, Preston C. , Kim, Isaac Yi , Saperstein, Lawrence, Rabil, Maximilian , Ghaffar, Umar , Karnes, R. Jeffrey , Ma, Xiaomei, Gross, Cary P. , Kunst, Natalia , Westvold, Sarah J. , Wang, Shi‐Yi , Leapman, Michael

Mayo Clinic

JAMA Network Open | October 23, 2024 | Volume: 7 | Issue: 10 | Pages: e2440591

10.1001/jamanetworkopen.2024.40591 | PMID 39441595 Get It

ImportanceAlthough prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown improved sensitivity and specificity compared with conventional imaging for the detection of biochemical recurrent (BCR) prostate cancer, the long-term outcomes of a widespread shift in imaging are unknown.ObjectiveTo estimate long-term outcomes of integrating PSMA-PET into the staging pathway for recurrent prostate cancer.Design, Setting, and ParticipantsThis decision analytic modeling study simulated outcomes for patients with BCR following initial definitive local therapy. Inputs used were from the literature and a retrospective cohort study conducted at 2 institutions. The base case analysis assumed modest benefits of earlier detection and treatment, and scenario analyses considered prostate-specific antigen (PSA) level at imaging and different outcomes of earlier vs delayed treatment. The analysis was performed between April 1, 2023, and May 1, 2024.Exposures(1) Immediate PSMA-PET imaging, (2) conventional imaging (computed tomography and bone scan [CTBS]) followed by PSMA-PET if CTBS findings were negative or equivocal, and (3) CTBS alone.Main Outcomes and MeasuresThe main outcomes were detection of metastases, deaths from prostate cancer, and life-years and quality-adjusted life-years (QALYs) gained.ResultsThe model estimated that per 1000 simulated patients with BCR (assumed median age, 66 years), PSMA-PET is expected to diagnose 611 (95% uncertainty interval [UI], 565-656) patients with metastasis compared with 630 (95% UI, 586-675) patients diagnosed using CTBS followed by PSMA-PET and 297 (95% UI, 202-410) patients diagnosed using CTBS alone. Moreover, the estimated number of prostate cancer deaths was 512 (95% UI, 472-552 deaths) with PSMA-PET, 520 (95% UI, 480-559 deaths) with CTBS followed by PSMA-PET, and 587 (95% UI, 538-632 deaths) with CTBS alone. Imaging with PSMA-PET yielded the highest number of QALYs, which were 824 (95% UI, 698-885) higher than CTBS. These results differed by PSA level at the time of testing, with the highest incremental life-years and QALYs and lowest number of deaths from prostate cancer among patients with PSA levels of at least 5.0 ng/mL. Finally, the estimates were sensitive to the expected benefit of initiating therapy for recurrent prostate cancer earlier in the disease course.Conclusions and RelevanceThe results of this decision-analytic model suggest that upfront PSMA-PET imaging for the evaluation of BCR is expected to be associated with reduced cancer mortality and gains in life-years and QALYs compared with the conventional imaging strategy, assuming modest benefits of earlier detection and treatment.
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Chen, Vincent , Morgan, Timothy R. , Rotman, Yaron , Patton, Heather , Cusi, Kenneth , Kanwal, Fasiha , Kim, W. Ray , Chen, V L , Patton, Heather M , Rotman, Yaron

Mayo Clinic

Hepatology | October 18, 2024 | Volume: 81 | Issue: 1 | Pages: 312-320

10.1097/hep.0000000000001112 | PMID 39422487 Get It

P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Hanft, Simon , Elder, B L, Giglio, Pierre , Wu, Siqi , Farrell, Christopher , Alnahhas, Iyad , Lee, I-Y., Walbert, Tobias , Boockvar, John A. , Aregawi, Dawit , Kim, L., Schulder, Michael , Singer, S, Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Jeyapalan, Suriya, Magge, Rajiv , Agarwal, Vijay , Amankulor, N, Quinones-Hinojosa, A, Neese, Laura L., Scott, Charles , Pérez‐Ollé, Raül, Andrews, David , Lee, Ian , Lee, Ian Y , Elder, B, Lee, I Y, Vojnic, Morana , Zacharia, Brad E. , Kim, L., Ghatan, Saadi , Wu, J, Patel, Nitesh V. , Bhatia, Ankush , Brennan, Cameron , Evans, L, Gill, B, Sengupta, Soma , Wong, Eric T. , Amankulor, N, Quinones-Hinojosa, A, Andrews, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v67-v68

10.1093/neuonc/noae144.222 Get It

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. In a phase 1b study in patients with ndGBM, IGV-001 was well tolerated without unexpected adverse events. Multiple efficacy signals were also observed, including significant improvements in progression-free survival, overall survival, radiographic evidence of tumor response, and changes in immune response biomarkers. A phase 2b randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of IGV-001 in patients with ndGBM (ClinicalTrials.gov identifier: NCT04485949) is ongoing. Here, we present the first safety data from the study. MATERIAL AND METHODS After surgical resection, patients are treated with IGV-001 or placebo followed by SOC. The study will enroll approximately 93 patients at 20 sites in the United States, with a 2:1 randomization favoring IGV-001. The primary outcome is progression-free survival, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety. RESULTS As of February 2, 2024, a total of 72 patients have been randomized and 69 have been implanted with IGV-001 or placebo plus SOC. The median age was 60.0 years (range, 24-70 years). Most randomized patients (76.4%) were 51-70 years of age, and the male:female ratio was 2.27. A total of 39/45 (86.7%) patients with enough follow-up time, initiated treatment with concurrent radiation and temozolomide. A total of 9/72 (12.5%) randomized patients discontinued treatment, including 7 patients who discontinued during the SOC treatment period. No patients discontinued treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized patients discontinued the study after randomization. CONCLUSION To date, the review of blinded safety data did not show any emerging risk and supports that there is no change to the benefit-risk profile of treatment with IGV-001 versus placebo. The data will be updated before presentation.